BN-82451 2HCl NEW
| Price | $293 | $722 | $987 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-20 |
Product Details
| Product Name: BN-82451 2HCl | CAS No.: 663172-95-0 |
| Purity: 99.84% | Supply Ability: 10g |
| Release date: 2024/11/20 |
Product Introduction
Bioactivity
| Name | BN-82451 2HCl |
| Description | BN-82451 2HCl is a dual inhibitor of COX-1 and COX-2 and can be used to study Huntington's chorea and Parkinson's disease. |
| In vivo | 1 - 10 mg/kg oral doses of BN82451 reduced the severity of fully established AIMs in a dose-related manner in a rat model of PD. This antimotor dysfunction effect was achieved with subchronic administration of lower doses of BN82451 compared with acute single treatments.The improvement in AIMs was not due to a reduction in general locomotor activity in the dyskinetic rats.BN82451 treatment significantly reversed the overexpression of c-Fos, FosB, and Arc mRNAs, which have been associated with the dyskinetic effects of levodopa.The effect of BN82451 was not due to a reduction in general motor activity in the dyskinetic rats. [1];After subchronic administration of 5 mg/kg/day subcutaneously for 5 days, IRC concentrations in the brain of male cynomolgus monkeys (Macaca fascicularis) were higher (cortex: 20.87±6.92 μM) than in plasma (1.16±0.33 μM), with a ratio of 18.2±2.5; at 2.5, 5, and 10 mg/kg IRC-082451, IRC concentrations in the brain of male cynomolgus monkeys were higher than in plasma (1.16±0.33 μM), with a ratio of 18.2±2.5. Subcutaneous injection into Macaca fascicularis quantified L-DOPA-induced dyskinesia and showed no significant effect on spontaneous motor activity in all acute treatments tested. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Keywords | BN82451B | BN-82451 HCl | BN 82451 | BN-82451 | BN 82451B | BN 82451 HCl | BN82451 | BN-82451B | BN82451 HCl |
| Inhibitors Related | Ibuprofen | Acetaminophen | Salicylamide | Diclofenac sodium | Diclofenac Potassium | Paradol | Indomethacin sodium hydrate | Trometamol | Glafenine | Revaprazan hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/1kg |
VIP2Y
|
Sichuan HongRi Pharma-Tech Co.,Ltd
|
2023-09-25 | |
| $195.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY